AZD2461: Novel PARP Inhibitor for Breast Cancer Research

Executive Summary: AZD2461 is a potent poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 5 nM, demonstrating cytotoxicity in MCF-7 and SKBR-3 breast cancer cell lines via PARP-1 inhibition and G2 phase cell cycle arrest (APExBIO). In vivo, AZD2461 reduces PAR levels in tumor-bearing mice for several hours post-treatment, with levels returning to baseline after 24 hours (Schwartz, 2022). AZD2461 displays lower affinity for P-glycoprotein (Pgp) than olaparib, addressing a key mechanism of drug resistance. It is well tolerated in long-term studies and significantly prolongs relapse-free survival in preclinical models. These properties position AZD2461 as a strategic tool for DNA repair pathway research in oncology.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are nuclear enzymes involved in DNA repair, genomic stability, and programmed cell death. PARP-1, the most abundant member, detects DNA single-strand breaks and facilitates repair by adding ADP-ribose polymers to target proteins. In BRCA1/2-mutated cells, homologous recombination is defective, making them reliant on PARP-mediated repair. Inhibiting PARP-1 in these cells leads to synthetic lethality, selectively killing tumor cells while sparing normal cells (Schwartz, 2022). Overcoming efflux-mediated resistance, notably via Pgp, is a critical goal in PARP inhibitor development. AZD2461, developed by APExBIO, addresses this by exhibiting lower Pgp affinity relative to first-generation inhibitors, expanding its utility in resistant tumor models (compare).

Mechanism of Action of AZD2461

AZD2461 competitively inhibits PARP-1, blocking its catalytic activity at a half-maximal inhibitory concentration (IC50) of 5 nM in biochemical assays (APExBIO). Upon DNA damage, PARP inhibition prevents ADP-ribosylation, impeding repair and causing accumulation of DNA breaks. This triggers cell cycle arrest with increased G2-phase and reduced S-phase populations in MCF-7 and SKBR-3 cells following 48–72 h incubation at 5–50 μM (Schwartz, 2022). In vivo, PAR levels in tumors decrease within hours after treatment and normalize at 24 h, supporting transient but robust pathway inhibition. Reduced Pgp affinity enables AZD2461 to retain intracellular levels and activity in multidrug-resistant models (clarifies).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 with an IC50 of 5 nM in vitro biochemical assays (APExBIO, product page).
• Exhibits concentration- and time-dependent cytotoxicity in MCF-7 and SKBR-3 breast cancer cells at 5–50 μM, 48–72 h (Schwartz 2022, DOI).
• Induces G2 cell cycle arrest and reduces S-phase fraction in treated cells (Schwartz 2022, DOI).
• In vivo, single-dose administration in KB1P tumor-bearing mice suppresses tumor PAR levels for several hours, returning to baseline after 24 h (Schwartz 2022, DOI).
• AZD2461 demonstrates lower affinity for Pgp than olaparib, enabling efficacy in Pgp-overexpressing tumor models (APExBIO, product page).
• Long-term dosing is well tolerated and significantly extends median relapse-free survival in mouse models (APExBIO, product page).

Applications, Limits & Misconceptions

AZD2461 is primarily suited for:

• In vitro studies of PARP-1 inhibition in breast cancer and BRCA1/2-mutated cell lines.
• Preclinical models of relapse-free survival and DNA repair pathway modulation.
• Overcoming Pgp-mediated drug resistance in experimental tumor systems (extends previous guide).

Compared to earlier articles such as "AZD2461 and the Next Frontier of PARP Inhibition", this dossier delivers an updated, citation-rich synthesis with direct emphasis on atomic benchmarks, storage, and preparation parameters.

Common Pitfalls or Misconceptions

• Not effective in non-PARP dependent tumors: AZD2461 is less effective in cell lines lacking PARP-1 dependence or BRCA mutations.
• Requires proper solvent: AZD2461 is insoluble in water; DMSO or ethanol (with ultrasonic assistance) is required for stock solutions.
• Not for extended solution storage: Prepare fresh solutions; long-term stock stability is not established.
• Not a clinical therapy: AZD2461 is for research use only and not approved for human administration.
• Limited by efflux in rare cell types: While Pgp affinity is lower, extreme Pgp expression may still reduce efficacy.

Workflow Integration & Parameters

• Solubility: ≥16.35 mg/mL in DMSO; ≥45.2 mg/mL in ethanol (ultrasonic assistance recommended).
• Storage: Store solid AZD2461 at -20°C; use solutions promptly.
• Experimental concentrations: 5–50 μM in cell culture; typical incubation 48–72 h.
• Cell lines: Validated in MCF-7, SKBR-3 (breast cancer), KB1P (mouse tumor models).
• Readouts: Cell viability (relative and fractional), cell cycle distribution (G2/S phase), and PAR levels.
• For protocol troubleshooting, see AZD2461: Novel PARP Inhibitor Transforming Breast Cancer ..., which this article updates by including explicit storage and solubility recommendations.

Conclusion & Outlook

AZD2461, as supplied by APExBIO (A4164 kit), is a robust research tool for dissecting PARP signaling pathway function in breast cancer and DNA repair studies. Its low IC50, efficacy in Pgp-overexpressing models, and well-documented tolerability distinguish it from earlier inhibitors. Researchers should note its solubility profile and storage requirements for optimal experimental reproducibility. Future directions include further benchmarking in additional tumor types and combinatorial strategies with DNA-damaging agents (Schwartz, 2022).